SCHEMBL30921024

SCHEMBL30921024

COC(=O)Nc1cc(-c2ccc(F)c(C)n2)ccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 14/20 0.58
DAPK1 P53355 3/20 0.58
MKNK2 Q9HBH9 3/20 0.58
BMP2K Q9NSY1 3/20 0.58
GAK O14976 2/20 0.58
MKNK1 Q9BUB5 2/20 0.58
MYLK2 Q9H1R3 2/20 0.58
HTR2B P41595 1/20 0.58
KCNH2 Q12809 1/20 0.58
PIK3C3 Q8NEB9 4/20 0.51
DAPK3 O43293 2/20 0.50
JAK2 O60674 2/20 0.50
HIPK4 Q8NE63 2/20 0.50
CIT O14578 1/20 0.50
MAP2K1 Q02750 1/20 0.50
PKN2 Q16513 1/20 0.50
TLK2 Q86UE8 1/20 0.50
STK39 Q9UEW8 1/20 0.50
TLK1 Q9UKI8 1/20 0.50
ROCK2 O75116 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24897751 1.00 AAK1 (0.58) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL27220588 0.88 TGFBR1 (0.49) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL30185619 0.84 AAK1 (0.62) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL24897652 0.84 AAK1 (0.62) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL21508497 0.78 AAK1 (0.56) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL25983881 0.78 AAK1 (0.55) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL25595134 0.77 AAK1 (0.47) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL30185675 0.76 AAK1 (0.77) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL24897635 0.76 AAK1 (0.77) AAK1DAPK1MKNK2BMP2KGAK
SCHEMBL30185612 0.76 AAK1 (0.77) AAK1DAPK1MKNK2BMP2KGAK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240343720-A1 AAK1 INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-10-17 US disclosed
EP-4371980-A1 AAK1 INHIBITOR AND USE THEREOF Xizang Haisco Pharmaceutical Co., Ltd. (CN) 2024-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343720-A1 AAK1 INHIBITOR AND USE THEREOF AAK1, ADCK1, ADCK5 AAK1 1/4885DAPK1 52/4885MKNK2 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.